Results 21 to 30 of about 123,989,332 (223)
Alpha-1 antitrypsin deficiency gut microbiome
This dataset contains 16S rRNA Illumina MiSeq sequenced samples used in our gut microbiome study in individuals with alpha-1 antitrypsin deficiency (AATD) and controls (non-AATD)
Kirst, ME (University of Florida)
core +1 more source
Serum alpha-1-antitrypsin level in Iraqi patients with coronary heart disease
This study was designed to estimate the level of serum alpha -1- antitrypsin in patients with coronary heart disease. Patients were clinically subdivided into stable angina 25 patients, unstable angina30 patients and myocardial infarction 50 patients. A
Asmaa M. Salih
doaj +1 more source
BACKGROUND:Alpha-1-antitrypsin is a protein involved in avoidance of different processes that are seen in diabetic retinopathy pathogenesis. These processes include apoptosis, extracellular matrix remodeling and damage of vessel walls and capillaries ...
María Constanza Potilinski +6 more
doaj +1 more source
What Is Alpha-1 Antitrypsin (AAT) Deficiency? Fact Sheet [PDF]
Basic facts about alpha-1 antitrypsin deficiency, managing your alpha-1 antitrypsin deficiency, how alpha-1 antitrypsin deficiency affects ...
core
Alpha-1 Antitrypsin Deficiency: Home Therapy
While available in only a few countries, home therapy is a possible strategy for the treatment of alpha-1 antitrypsin deficiency. We want to describe our experience in the management of human alpha-1 antitrypsin using home care intravenous augmentation ...
Anna Annunziata +5 more
doaj +1 more source
The Impact of Systemic Treatment With Flunixin Meglumine on the Two Antiproteases Alpha-2-Macroglobulin (A2M) and Alpha-1-Antitrypsin (A1AT) in Equine Plasma and Platelet-Rich Fibrin (PRF). [PDF]
ABSTRACT Purpose To evaluate the effect of flunixin meglumine, a systemic non‐steroidal anti‐inflammatory drug (NSAID), on the antiproteases, A2M and A1AT, in equine plasma and PRF. Methods A prospective cross‐sectional study. Plasma, solid PRF, and liquid PRF were collected from a control‐group that included healthy horses not treated with NSAIDs ...
Scheunemann KR +6 more
europepmc +2 more sources
Clinical features in patients with severe Alpha-1 antitrypsin deficiency due to rare genotypes
Alpha-1 Antitrypsin Deficiency (AATD) is a co-dominant condition associated with an increased risk of lung and liver disease. Since it is commonly thought that 95% of severe cases of AATD have PI*ZZ genotype, most studies about AATD have been focused on ...
Ilaria Ferrarotti +18 more
doaj +1 more source
Alpha-1 antitrypsin deficiency (AATD) is one of the most common genetic diseases and is caused by mutations in the SERPINA1 gene. The homozygous Pi*Z variant is responsible for the majority of the classic severe form of alpha-1 antitrypsin deficiency ...
Nélia Abreu +3 more
doaj +1 more source
Alpha-1-Antitrypsin Deficiency
Homozygous PIZZ alpha 1-antitrypsin deficiency, which has an incident of 1 in 1600 to 1 in 2000 live births, is the most common genetic cause of liver disease in children. It is also associated with chronic liver disease and hepatocellular carcinoma in adults. It is a well-known cause of pulmonary emphysema.
Paone G, Brantly M.
openaire +5 more sources
Alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition caused by decreased plasma and tissue levels of alpha-1 antitrypsin (AAT) that can lead to serious lung and liver disease in children and adults. AATD patients face challenges such as under diagnosis, clinical variability, and limited treatment options for liver disease.
openaire +4 more sources

